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ABSTRACT

Minser, Kayla E. M.S., Purdue University, May 2014. Neurotrophins and Their Effects on
Breast Cancer Cell Proliferation and Migration. Major Professor: Julia Kirshner.
Cancer is a large health issue in all parts of the world. In the United States
alone, approximately 1 in 4 deaths are cancer related. Breast cancer is a particularly
prevalent form, accounting for a little over 14 percent of all cancer incidence. The largest
obstacle to overcome for breast cancer morbidity is metastasis. Over 90 percent of all
breast cancer related deaths are due to metastasis. Because metastasis is a complex,
multi-step process, it is difficult to treat. A recent observation in the Kirshner lab has
revealed a type of phenotypic plasticity, where migratory cancer cells have a neuronallike morphology with multiple axon-like projections.

This observation has led to an

interest in the characteristics of these cells and how they relate to metastasis. One of
the characteristics is receptivity to neurotrophins, which are neuronal growth factors. We
have shown that MCF10CA1a cells, a malignant progression of the MCF10 series, do
express three neuronal receptors, TrkA, TrkB, and p75NTR in both 2D and 3D cell culture.
Addition of neurotrophins, NGF, BDNF, and NT 4/5 increase proliferation between 24
and 72 hours of treatment in 2D cell culture. Further, addition of NGF and NT 4/5 act as
a chemoattractant to these cells, increasing their migration towards the neurotrophin.
From these results we conclude that neurotrophins do have an effect on the proliferation
and migration of breast cancer cells. This could serve as a therapeutic target for future
treatment of breast cancer and breast cancer metastasis.
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CHAPTER 1. INTRODUCTION

1.1 Breast Cancer
1.1.1

Breast Cancer Incidence

Cancer is a large health obstacle in all parts of the world. In the United States
alone, approximately 1 in 4 deaths are cancer related. Each type of cancer has its own
complications, symptoms, and treatments, but the commonality in all of them is the
diminished quality of life and an increased mortality rate. Breast cancer is a particularly
prevalent form, accounting for a little over 14 percent of all cancer incidence1. The
American Cancer Society estimates that over 235,000 people in the United States will be
diagnosed with breast cancer in 2014 alone and over 40,000 of them will succumb to the
disease. It is vital to study and research breast cancer in order to reduce the mortality
rate and improve quality of life for those diagnosed with the disease.
1.1.2 Metastasis
The largest obstacle to overcome for breast cancer morbidity is metastasis. Over
90 percent of all breast cancer related deaths are due to metastasis2. Over time the
rates of breast cancer metastasis have increased. The American Medical Association
has reported that metastatic breast cancer in women under 40 has increased 2 percent
a year, ever year, from 1976 to 20093. Because metastasis is a complex and multi-step
process, it is very difficult to treat and even more difficult to research the mechanisms
involved in the process. Unfortunately, little is known about the populations of cells that
are able to leave a primary site and colonize a secondary site in the body, nor is there
much information on the signaling pathways that are involved in the process. The
heterogeneous nature of metastasis makes it difficult to understand. In order to treat
breast cancer and reduce the mortality of the disease, it is important to understand the
mechanisms of metastasis so that they can be targeted as methods of treatment.
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Metastasis is characterized by cells that are able to leave the primary tumor site
and eventually colonize and proliferate in a secondary site in the body4. The bone is
one of the most common secondary sites of breast cancer metastasis. Other sites
include brain, liver, lung, and lymph nodes5. Metastasis was previously characterized as
a latent, acquired phenotype of primary breast cancer tumorigenic cells6. More recently,
however, it was shown that the ability of cells to metastasize is an inherent feature of
breast cancer7.
The process of metastasis is very complex and is referred to as the invasionmetastasis cascade. It is characterized by specific steps that allow epithelial cells to
colonize distant sites in the body. In order for metastasis to occur, the first step that an
epithelial cell must take is to invade the local tissue area. This includes breaking
through the extracellular matrix (ECM) components and basement membrane, followed
by invasion of the surrounding stroma8. The basement membrane is a crucial part of the
metastastic cascade because of the growth factors that it contains and the vital role that
it plays in signal transduction pathways of the carcinoma cell9. These pathways include
changing of cell polarity, invasiveness, proliferation and survival10. To further overcome
invasion obstacles some cancer cells will undergo epithelial-to-mesenchymal
transition(EMT)8. EMT includes the suppression of epithelial markers, such as Ecadherin and cytokeratin, that allow the cell to exhibit mesenchymal traits, most
importantly, increased invasiveness11-13. The next step is intravasation, whereby the
cancer cell must break through components of vessels such as the pericyte and
endothelial cell barriers and enter into a blood or lymphatic vessel14. This process may
be facilitated by increased angiogenesis in the primary tumor area15. Further, the new
vessels that are formed near the tumor area can be leaky and poorly constructed aiding
in an easier invasion of the vessel itself16. After the cell completes intravasation it must
then be able to survive in a non-adherent state as it travels through the vasculature.
This is seemingly difficult for an epithelial cell because cell survival is generally
dependent on integrin-dependent adhesion to ECM components17. Cells unable to
adhere usually undergo anoikis18. Once the cell is in circulation, it will arrest in a
capillary in a distant location. It is unknown whether the metastatic tropism arises from
the large epithelial cell simply getting stuck in a microvessel, or if certain cancer cells
have a preference for particular organs and their ECM components19. After the cell is
arrested in the microvessel it must break through the lumina of the vessel and enter into
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the functional tissue of the organ, a process called extravasation20. The cell must then
survive in a new tissue microenvironment, which includes a new ECM makeup, growth
factors and cytokines, and different types of stromal cells. The cell must survive long
enough to form micrometastases and turn on proliferative programs that allow for
neoplastic growth and full colonization of the distant site21. This is particularly difficult for
the cells to accomplish as they have limited supply to vessels and must adjust to a new
microenvironment. In addition, the cells must have a high proliferation capacity in order
to sustain a population of cells that successfully colonize a distant site. It is obvious that
the metastatic cascade is extremely complex22. There are many growth factors,
cytokines, signaling pathways and genes that are involved, which is where difficulties
arise in studying the process and further treating it in patients. In order to reduce the
morbidity of breast cancer, it is important to understand more about these pathways and
factors in the metastatic cascade. It is possible that some of the pathways involved in
the metastatic cascade are not as obvious as it would seem. A recent study in the
Kirshner lab has used a reconstructed metastasis model (rMet) as a way to study
metastasis in vitro and has led to a new vein of research involving the connection of
breast cancer cells and neurons. It has been observed in the rMet model that a
population of breast cancer cells that have migrated and colonized the secondary
environment display a neuronal-like morphology. This includes multiple axon-like
extensions and even growth cone-like structures. This has been observed in multiple
breast cancer cell lines and even other cancer cell lines such as lung and prostate
cancers. This has led to the interest in the characteristics of these neuronal-like cells
and how these characteristics contribute to metastasis.
1.2
1.2.1

Neurons

Neuronal Morphology and Function

Neurons are a unique class of cells that make up the nervous system. They are
able to transmit information through chemical and electric signals. Though they contain
similar internal structures to all other cells in the body, they have many morphological
differences that make them unique. Structurally, they can be divided into three different
parts: the cell body or soma, dendrites, and axons23. The soma is the main body of the
neuron and is where the nucleus and other cellular compartments are located. The
soma can range from 6 to 80 µm in diameter23. Dendrites and axons are both
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extensions from the cell body. The axon can be classified into four distinct sections: the
axon hillock, the initial segment, the axon proper, and the axon termination23. The axon
is responsible for sending chemical and electrical signals away from the cell body. They
are composed of neurotubules and neurofilaments24. Electric signals originate in the
axolemma of the initial segment. The terminal end of the axon widens at the synaptic
regions, where synapses will send chemical or electrical signals to other neurons25.
Dendrites are also arranged around the soma in a stellate manner and are responsible
for afferent communications. They extend from the cell body in a single trunk but branch
out towards the end to form a dendritic tree26. Axon terminals have a common boundary
with dendrites. The synaptic area at the axon terminal is where communication between
neurons occurs. Synaptic messages can either be excitatory, inhibitory or modulatory27.
1.2.2

Neuronal Development

Developmentally, neurons arise from the ectoderm in the form of the neural
28

tube . The neural tube is a single layer of epithelial cells and these epithelial cells are
the progenitors of both neurons and glial cells29. Neural stem cells (NSC) are extremely
prolific at the beginning of development, but their numbers are quickly diluted with the
presence of restricted progenitor cells and differentiated neural or glial cells. NSCs are
derived from pluripotent embryonic stem cells30. Neuroepithelial cells of the neural tube
are self-renewing but do not always have unlimited divisions31. They can be multipotent,
giving rise to multiple, limited cell types, or possible even unipotent, giving rise to only
one cell type. Additionally, their divisions might be symmetric, with both daughter cells
identical to the mother, or asymmetric, giving rise to two functionally separate daughter
cells, one identical to the mother cell and one that is not32. Neuroepithelial cells can
undergo symmetric, proliferative division, giving rise to two identical neuroepithelial cells.
Further divisions, however, may be asymmetric and account for neurogenic division32.
This division will give rise to two functionally different nervous system cells, a glial cell
and a neural progenitor that will give rise to two identical neurons. The glial cell can then
undergo another asymmetric division, giving rise to an identical daughter cell and
another neural progenitor that will give rise to two neurons33. Neural progenitor cells
themselves are non-functional cells and have a limited number of divisions32. The radial
cell can also undergo symmetric division with two neural progenitor daughter cells that
will in total yield four neurons34. Once the cells differentiate into neurons, they are
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terminally differentiated and post-mitotic. The ability of a cell to undergo symmetric or
asymmetric division is dependent upon the location of the cleavage plane during
division. If the cleavage plane is positioned vertically, the division will be symmetric
because equal apical and basal components will be transferred to both daughter cells.
Conversely, if the plane is oriented horizontally, the division will be asymmetric because
apical components will be given to one daughter cell and basal components will be given
to the other daughter cell32. After differentiation, cells migrate through the body to their
specified area of the CNS.
1.2.3 Neuronal Development and Neurotrophins
After migration, the neurons go through a maturation stage. In this stage their
number of processes increases and they create a complex connection of neuronal cells
that form the central nervous system. The manner in which these neuronal cells
differentiate and form the complex network of the CNS is still not fully understood. There
is however, evidence that neurotrophins play an important role in the development35.
Neurotrophins are dimeric, secretory proteins found primarily in the developing nervous
system. They are extremely important for neuronal differentiation, proliferation, survival,
and axon wiring, and exist in a family of four proteins36. They are Nerve Growth Factor
(NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3) and
Neurotrophin-4/5 (NT-4/5). The neurotrophin transcripts are all translated into precursor
proteins called proneurotrophins. They are all relatively the same size and contain the
mature neurotrophin within them37-39. The proneurotrophins are cleaved at a specific
amino acid site. This cleavages yields the mature neurotrophin. The neurotrophins
exert their effects through their receptors, p75NTR, a low-affinity receptor, and three
tyrosine kinase receptors (TrkA, TrkB, TrkC), all high-affinity receptors38. It has been
shown that all four neurotrophins are involved in both tropic and trophic axonal
outgrowth. Chemotropic effects have been observed in growth cones of certain
neuronal populations in vitro as well40. The effectiveness of the neurotrophin on neurite
outgrowth is not uniform; some neurotrophins such as BDNF, having a greater impact on
neurite outgrowth and lamellepodial activity than others41. Further, there is evidence that
there must be a balance between the presence of the different neurotrophins because
some neurotrophins have inhibitory effects on other members of the family42. Not only
do neurotrophins have effects on axonal outgrowth, they also can exert their effects on
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dendritic growth. They can have effects on the connections that neurons make with
each other and there is evidence that suggests that neurotrophins may even be involved
in synapse formation and maturation37. Not only can neurotrophins have an effect on
neurons, but there are also a wide variety of cell types that show proliferation,
differentiation or survival benefits when in the presence of neurotrophins43.
1.3

Neurotrophins and Signal Transduction

It is obvious that neurotrophins play a role in the growth, survival and proliferation of
different cell types. In order to accomplish this, neurotrophins exert their effects through
their receptors and the subsequent signaling pathways that are activated. As previously
mentioned, there are four neurotrophin receptors. P75NTR, is a low-affinity receptor. The
other three, TrkA, TrkB, and TrkC, are all tyrosine kinase receptors that are high-affinity
receptors. The Trk receptors are characterized by an intracellular tyrosine kinase
domain, a transmembrane domain, and the extracellular domain containing an
immunoglobulin-like domain and a leucine-rich region in between two cysteine-rich
regions38. All four of the neurotrophins bind with equal affinity to p75NTR. The Trk
receptors bind more specifically, but there is still overlap in the neurotrophins and the
receptors44. For example, NGF binds primarily to TrkA, but both BDNF and NT-4/5 bind
to TrkB. NT-3 binds primarily to TrkC, but for the purpose of the research put forward,
will not be covered in depth (Figure 1-1). When a neurotrophin binds to it’s receptor, the
trk receptors dimerize, which allows for autophosphorylation44. The overall process can
lead to the activation of a number of signaling pathways such as mitogen-activated
protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ
(PLC-γ)45, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κΒ)46.
The particular pathway that is activated is dependent on the dimerization of the
receptors and the neurotrophins that have bound to them. There are a variety of ways
that the receptors can dimerize and certain receptors have higher affinity for each other
than others47. All neurotrophins can bind to p75NTR 45. This receptor can dimerize with
other receptors, but can also activate subsequent signaling pathways without
dimerization. When a neurotrophin binds to p75NTR and it does not dimerize, there is
evidence that NF-κΒ is activated, which can lead to cell survival, or resistance to
apoptosis46. This pathway is also activated when NT-4/5 or BDNF bind to TrkB and
TrkB dimerizes with p75NTR. Though TrkB can dimerize with p75NTR, there is no
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Figure 1-1 Neurotrophin Binding and signaling pathways. Dashed lines
show low affinity binding to p75NTR. Solid lines show high affinity binding.
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evidence that TrkA or TrkC have any affinity for binding to p75NTR 47. When NT-4/5 or
BDNF bind to TrkB and TrkB dimerizes with another copy of itself the pathway activated
is still unknown but has been suggested that it can lead to increased invasion
capabilities. Binding of NGF to TrkA, where TrkA dimerizes with another TrkA, leads to
the activation of one of three pathways. They are the MAPK pathway, which leads to
proliferation and possibly even an increase in invasion, PI3K pathway, which can
increase cell survival, and the PLC-γ pathway, which in neurons aids in synaptic
plasticity45. The interaction between NGF and TrkA also leads to sensory neuron’s
ability to detect temperature and pain48. It is obvious that the pathways and the binding
of the receptors are not very straightforward. The ways in which neurotrophins can bind
to their receptors and the way the receptors dimerize is complex and leads to difficulties
in fully understanding the subsequent pathways that are activated. More work in the
field will need to be completed to fully understand the way in which the neurotrophins
exert their effects on not only neuronal cells during neuronal development, but also other
cell types.
1.4 Neurotrophins and Cancer
More recently there has been an increase in the research conducted on
neurotrophins and their effects on cancer cells. Because there is growing evidence that
neurotrophins can exert their effects on non-neuronal cells, it seems that there might be
a connection between neurotrophins and cancer as well. There have been many groups
that have identified the expression of neurotrophin receptors in cancers such as lung,
breast, prostate, nueroblastoma and medulloblastoma49-52. We can reasonably infer that
if the receptors are actively expressed in cancer cells that neurotrophins might have an
effect on the proliferation and survival of those cells. Of particular interest are the Trk
receptors. The Trk gene has been cloned as an oncogene and can be involved in
human cancers as a proto-oncogene53. When the Trk receptor is fused with the
tropomyosin in the intracellular domain, the receptor becomes constitutively active54.
This leads to continuous cell proliferation. This fusion of the Trk receptor has been
observed in acute myeloid leukemia, colon cancer and thyroid cancers52,55. It has also
been shown that alteration of the immunoglobulin-domain of the Trk receptors in the
extracellular domain causes constitutive phosphorylation and dimerization of the TrkA
receptor, which can lead to a malignant phenotype of the cells56. Interestingly, these
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characteristics were originally found in cancers that are not of neuronal origin. As a
proto-oncogene, there is evidence that mutation or rearrangement of the DNA of the Trk
gene can lead directly to tumorigenesis in cancers of neuronal origin52. In
neuroblastomas there is an increased expression of TrkB, which paired with it’s
neurotrophin binding partners can confer an increased invasion and metastatic capability
to the cancer cells57,58. It has been suggested that Trk intracellular signaling is
deregulated in cancer cells leading to increased activity of proliferation pathways52. In
addition to this research there has been more interest in the expression of neurotrophin
receptors and the neurotrophins in breast cancer. Similar to the work completed in
neuroblastomas, there has been work concerning TrkA and NGF in breast cancer as
well. It has been shown that when NGF binds to TrkA, there is stimulation on cell
proliferation through the MAPK pathway in multiple breast cancer tumor-derived cell
lines59. It has also been shown that NGF binding to p75NTR leads to an anti-apoptotic
effect in breast cancer cell lines60. The autocrine stimulation of these pathways has
confirmed NGF as a growth factor that can contribute to the progression of breast
cancer. TrkA has also been shown to work with HER2 to activate breast cancer cell
proliferation59. There is also evidence that NGF is overexpressed in many breast cancer
tumors61. Additionally, TrkB and its ligands BDNF and NT4/5 are expressed in breast
cancer cell lines and this activity can lead to resistance to anoikis62. The knowledge
regarding the full activities and pathways that are activated in breast cancer are still
lacking, however, which has led to the current vein of research.
It is important to understand the growth factors and pathways that could be
involved in the malignancy that is observed in breast cancer. If particular proliferation
pathways or pathways that lead to aversion of apoptosis are evident in breast cancer, it
is possible to develop treatments that can block these pathways. For example,
tamoxifen has been shown to block the proliferative effects of NGF63. However,
relatively little is known about the neurotrophins and their effects on non-neuronal cells.
Preliminary research has shown that this is a promising direction to take in cancer
research. Metastasis is the cause of most breast cancer morbidity and the
neurotrophins and their signaling pathways may be able to reduce the migratory and
invasive capabilities of metastatic breast cancer cells. If we can treat metastasis more
specifically, then we can significantly decrease the mortality rates of breast cancer and
increase the quality of life of those who are diagnosed.
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CHAPTER 2. MATERIALS AND METHODS

2.1
2.1.1

Tissue Culture

Cell Lines and Cell Culture

MCF10CA1a cells were obtained from Barbara Ann Karmanos Cancer Institute
and were cultured in DMEM/F-12/HAM media (Sigma) supplemented with 5% horse
serum (Sigma). MCF7 (ATCC) cells were cultured in RPMI-1640 media (Sigma)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin
(Sigma). Immortalized human fetal bone marrow mesenchymal stem cells (hTERTMSC) were a kind gift from Dr. Carlotta Glackin (Beckman Research Institute, City of
Hope National Medical Center) and were cultured in αMEM (Sigma) supplemented with
10% FBS, 1% penicillin-streptomycin, and 1% L-Glutamine (Sigma). All cell lines were
cultured at 37°C in 5% CO2 tissue culture incubator. Bone marrow growth media
(BMGM) consisted of RPMI-1640 supplemented with 6.2 x 10-4M CaCl2, 1x10-6M sodium
succinate, 1x10-6M hydrocortisone, 20% FBS, and 1% penicillin-streptomycin. Bone
marrow condition media (BMCM) was obtained by collecting BMGM that had been
conditioned by cultures of hTERT-MSCs.
2.1.2

2-D Proliferation Assay

MCF10CA1a cells were grown to confluency in MCF10CA1a growth medium.
The cells were then dissociated from the surface of the tissue culture vessel by 0.25%
trypsin-EDTA (Sigma) digestion. Eighty thousand cells were seeded into each well of a
48-well tissue culture plate (BD Falcon) in 400 µl of growth medium. Twenty-four hours
post-plating, the growth media was removed and cells were washed with 1X PBS
(Sigma). Neurotrophins: BDNF, NT4/5, and NGF were diluted from an initial stock
concentration of 0.5 mg/ml in DMEM/F-12/HAM supplemented with 1% horse serum.
Working concentrations for each neurotrophin were 5, 50, 100, and 200
ng/mL[reference]. The vehicle control treatment consisted of DMEM/F-12/HAM
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supplemented with 1% horse serum and 0.1% bovine serum albumin (Sigma). Bovine
serum albumin was the vehicle control because it was used to make the stock
concentrations of neurotrophins, NGF and NT 4/5. Cells were treated with neurotrophins
for 24 or 48 hours, treatments were removed by aspiration, and cells were rinsed with 1X
PBS. To determine the effect of each neurotrophin concentration on cell growth, viable
cells were counted based Trypan Blue (Sigma) exclusion.
2.1.3
2.1.3.1

rMet Model Setup
Matrix Preparation

Rat-tail collagen type I (BD Biosciences) was first diluted to 2 mg/ml solution in
neutralization buffer that contains 100 nM HEPES (Sigma) in 2X PBS with a pH of 7.27.4. Reconstructed endosteum (rEnd) was made using the 2 mg/ml rat-tail collagen type
I (BD Biosciences) and fibronectin from human plasma (Millipore) to a final concentration
of 77 µl/ml and 29 µl/ml, respectively, in a 1X PBS (Sigma). rBM comprised of 3.7 parts
Matrigel (BD Biosciences), 2.4 parts fibronectin (1 mg/ml) and 1 part collagen I (2
mg/ml).
2.1.3.2

rMet Assembly

To set up the “distant metastatic site” rEnd, rBM and BMCM were used in a
tissue culture plate well. The wells of a 24 well plate (BD Falcon) were first coated with
recontstructed endosteum (rEnd) for 1 hour at 37°C. The excess liquid was removed and
75 µl of reconstructed bone marrow (rBM) was added to each well and incubated for 1
hour and 37°C. This process forms a semi-solid layer of matrix in a tissue culture well.
After this, 1 ml of warm BMCM was added to the well to complete the “distant metastatic
site” setup. The “primary tumor environment” was set up in 24-well format cell culture
inserts with membrane pores of 8 µm (BD Biosciences). MCF10CA1a cells grown to
confluency were mixed with Matrigel at 2.5 × 104 cells/5 µl 1X PBS per insert. The
Matrigel/cell suspension was added to the insert and incubated for 30 minutes at 37°C.
After the 30-minute incubation period, 0.5 ml of warm epithelial growth medium [EGM:
RPMI-1640 supplemented with 1% horse serum and 1% penicillin-streptomycin (Sigma)]
was added to the top of the Matrigel/cell mixture.
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2.1.4

rMet Proliferation Assay

Following the culture of MCF10CA1a cells in the rMet model for 14 days, cell
culture inserts were removed from their wells and discarded. The wells were then rinsed
with warm 1X PBS (Sigma). Metastatic cells growing in the bottom chamber of the rMet
assay were treated with neurotrophins as follows: BDNF at 5 ng/ml, NT4/5 at 50 ng/ml,
NGF at 50 ng/ml, all diluted in DMEM/F-12/HAM supplemented with 1% horse serum.
These concentrations were chosen based on the data obtained from the 2-D proliferation
assay. The vehicle control treatment consisted of 0.1% bovine serum albumin in
DMEM/F-12/HAM supplemented with 1% horse serum. The BMCM medium from each
well was removed and rinsed with PBS before new treatments were added. Each
treatment was added to its respective well at a volume of 0.4 ml. Cells were treated for
24 or 72 hours, the treatments were removed and wells were washed with 1X PBS.
Cells were then fixed in 10% neutral buffer formalin (1X PBS with 10% formalin) for 15
minutes. The cell membranes were then permeabilized with a solution of 0.1% Triton X100 (Sigma) in 1X PBS for 10 minutes. Non-specific binding sites of cells were blocked
with a 1% bovine serum albumin in 1X PBS for 1 hour. Ki67 antibody (Rabbit mAb,
Alexa Fluor® 647 Conjugate; Cell Signaling) was added at a dilution of 1:50 in 1% BSA in
1X PBS for a total volume of .15 mL per well, for 1 hour at room temperature. Nuclear
Isolation and Staining Solution (NPE Systems) was added at 1:25 dilution and was
incubated for 5 minutes. Each step was preceded by two 1X PBS washes to remove
each solution. Cells were then imaged using Zeiss AxioObserver inverted microscope
equipped with AxioVision software 4.7.3 (Zeiss).
2.1.5 Dome Assay for Cell Migration
MCF10CA1a cells were grown to confluency in growth media. Cells were
counted, centrifuged, and after centrifugation, supernatant was removed and cells were
resuspended in 5 µl PBS per sample. Cell suspension was added at a volume of 5 µl to
20 µl matrigel. A circle in the center of the well, as well as a dotted grid were drawn on
the bottom of a 24 well plate (BD Falcon). The 25 µl of Matrigel/cell mixture was
carefully pipetted into the center circle that was drawn on the bottom of the plate, and
the plate was incubated for 30 minutes at 37°C. For the treatment ring of the dome
assay, neurotrophins were diluted to their final concentration in 75 µl matrigel (BDNF at
50 ng/ml, NT4/5 at 5 ng/ml, NGF at 5 ng/ml). The 75 µl matrigel/neurotrophin mixture
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was added to the periphery of the well and incubated for 30 minutes at 37°C. Finally,
0.5 ml of warm MCF10CA1a growth media was carefully added to each well and plates
were incubated for 24 hours at 37°C in a 5% CO2 incubator. To visualize spreading
cells, wells were rinsed with warm PBS and stained with calcein (Life Technologies) with
a final concentration of 1 µM. Cells were imaged using the Zeiss AxioObserver inverted
microscope equipped with AxioVision software 4.7.3 (Zeiss). Counts were completed
based on cell migration out of the dome, and into the treatment ring.
2.2
2.2.1

Immunofluorescence

Neurotrophin Receptor Staining in 2-D

MCF10CA1a cells were seeded at 8.0 × 104 in 8 well chamber slides (Tetra-Tek)
in MCF10CA1a growth media. Twenty-four hours post-seeding, cells were rinsed with
1X PBS and fixed for 15 minutes in NBF. Cells were washed with 1X PBS and the
primary antibodies against NGFR, TrkA, and TrkB (R&D) were added to their respective
wells at a concentration of 1:200 in 1% BSA in PBS, for a final volume of 150 µl per well,
at room temperature for 1 hour. After primary antibody incubation cells were washed
with 1X PBS. Secondary antibodies were added at a concentration of 1:200 in PBS for a
final volume of 150 µl per well [Alexa Fluorofluor 555 donkey anti-mouse IgG (H+L) and
Alexa Flurofluor 647 donkey anti-goat IgG (H+L); Life Technologies] at room
temperature for one hour. After the incubation, Nuclear Isolation and Staining Solution
(NPE Systems) was added for 5 minutes at a concentration of 1:25 in 1X PBS. Cells
were immediately imaged on a Zeiss AxioObserver inverted microscope equipped with
AxioVision software 4.7.3 (Zeiss).
2.2.2

Neurotrophin Receptor Staining in rMet

MCF10CA1a cells were first seeded in the rMet model as described above. The
cells were cultured in the model for 14 days. On day 14, the rMet model was
deconstructed to isolate cells from the three separate levels of the model, the ‘primary
tumor’ site, the invasive fraction, and the ‘secondary site’ at the bottom of the model.
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2.2.2.1

Primary Tumor Site Cell Isolation and Neurotrophin Receptor
Immunofluorescence

The transwells were removed from the culture plate and rinsed twice with cold 1X
PBS. Cell Recovery solution (BD Biosciences) was added to each transwell at a volume
of 186 µl and vigorously pippetted. The Matrigel, cells, and recovery solution were then
transferred to a 15 ml tube (BD Biosciences). An additional 279 µl of Cell Recovery
Solution was added to each transwell and vigorously pippetted. The solution from each
transwell was transferred to a second 15 ml tube. Samples incubated on ice for 2 hours.
After incubation, tubes one and two were combined and 3 ml of MCF10CA1a growth
media was added. The cell suspension was centrifuged for 8 minutes at 1800 rpm. The
supernatant was removed and cells were resuspended in 120 µl of 1X PBS. Twenty µl
of the suspension was pippetted and spread onto a glass slide (VWR Micro Slide).
Slides were allowed to air dry, and then cells were fixed, stained and imaged using the
same procedure and reagents described above.
2.2.2.2

Invasive Fraction Neurotrophin Receptor Immunofluorescence

After the Matrigel/cell mixture was removed from the transwells, the membranes
of the transwells were removed from the transwell using a razor blade. The membranes
were then placed into their own individual wells in an 8 well chamber slide (Tetra-Tek)
and were fixed, stained and as described above.
2.2.2.3

rBM Fraction Neurotrophin Receptor Immunofluorescence

Media was first removed from the wells and the rBM/cell layer was rinsed twice
with warm 1X PBS. Wells were then fixed for 15 minutes in NBF. Cells were washed
with 1X PBS and the primary antibodies against NGFR, TrkA, and TrkB (R&D) were
added to their respective wells at a concentration of 1:200 in 1% BSA in 1X PBS, for a
final volume of 200 µl per well, at room temperature for 1 hour. After primary antibody
incubation, cells were washed with 1X PBS. Secondary antibodies were added at a
concentration of 1:200 in 1X PBS for a final volume of 200 µl per well[Alexa Fluorofluor
555 donkey anti-mouse IgG (H+L) and Alexa Flurofluor 647 donkey anti-goat IgG (H+L);
Life Technologies] at room temperature for 1 hour. After the incubation, Nuclear
Isolation and Staining Solution (NPE Systems) was added for 5 minutes at a
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concentration of 1:25 in 1X PBS. Cells were immediately imaged on a Zeiss
AxioObserver inverted microscope equipped with AxioVision software 4.7.3 (Zeiss).
2.3
2.3.1

Molecular Biology
RNA Extraction

RNA extraction was completed using a Direct-Zol RNA Miniprep kit (Zymo
Research). Extraction was completed according to the manufacturer’s instructions and
RNA was stored at -80°C. RNA was extracted from MCF10CA1a cells from the 2-D
culture, and from the primary tumor and rBM fractions of MCF10CA1a cells grown in the
rMet model.
2.3.2

Reverse Transcritption cDNA Synthesis

cDNA synthesis was completed using the Accuscript High Fidelity 1st Strand
cDNA Synthesis kit from Agilent Technologies according to the manufacturer’s
instructions.
2.3.3

Real-Time quantitative PCR (rt-qPCR)

rt-qPCR was completed using a DyNAmo HS Sybr Green qPCR kit (Thermo
Scientific). Four reactions were completed for each cell sample, one for each of the
neurotrophin receptors p75NTR, TrkA, TrkB and GAPDH (Table I)64. Cycling protocol was
completed on a 7300 Real Time PCR System (Applied Biosciences) and followed: 95°C
for 15 minutes; 30 cycles of 94°C for 10 seconds, 60°C for 30 seconds, 72°C for 30
seconds; followed by a melting curve analysis at 72°C -95°C for 20 minutes.
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Table I. Neurotrophin Receptor Primers
Receptor

Forward Primer (5’ – 3’)

Reverse Primer (5’ – 3’)

TGGACAGCGTCACGTTCTCC

GATCTCCTCGCATCGGCGT

TrkA

GCATCTGGAGCTCCGTGATC

CTCTGCCCAGCACGTCAAGT

TrkB

AGACACTCAGGATTTGTACTGCC

TCCGTGTGATTGGTAACATGTATT

GAPDH

CTGGGCTACACTGAGCACC

AAGTGGTCGTTGAGGGCAATG

p75

NTR
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CHAPTER 3. NEUROTROPHIC EFFECTS ON THE PROLIFERATION AND
MIGRATORY CAPABILITIES OF BREAST CANCER CELLS

3.1 Neurotrophins and Breast Cancer Cell Proliferation
Neurotrophins are important growth factors for the growth and development of
neuronal cells. Recent observations in the Kirshner lab have shown a phenotypic
plasticity of certain metastatic cancer lines that results in a population of cells that
resemble neurons. This observation has sparked an interest in neurotrophins and the
effects that they could exert on the proliferation and metastatic spread of breast cancer
cells.
In order to study the metastatic migration of cancer cells, an in vitro model
developed in the Kirshner lab was used65. This reconstructed metastasis, the rMet
model, is used to recapitulate multiple steps of the metastatic spread in vitro. This model
is a 3-D method that recapitulates breast to bone metastasis, but is also applicable to
other tumors and secondary sites with manipulation of ECM components. It is
composed of a transwell containing extracellular matrix (ECM) components to mimic the
mammary gland environment, or the “primary tumor” environment. The transwell is
inserted into a cell culture plate where the ECM and media mimic a distant site of
metastasis, in this case bone66,67 (Fig 3-1). Breast cancer cells seeded in the top must
migrate through the Matrigel, which is a mix of ECM components that is biologically
active and mimics the basement membrane, travel through the membrane of the
transwell, and then successfully attach and invade the reconstructed bone marrow
matrix (rBM) after existing in a non-adherent state in the bone marrow media (Figure 31b). rBM contains collagen I, fibronectin, collagen IV and laminin, which are all the
necessary ECM components to recapitulation bone marrow. The rMet model allows for
observation and study of the populations of cells that are capable of movement to a
secondary site. Further, it allows for manipulation of signaling pathways and growth
factors to determine their respective roles in metastasis. The growing cells in rMet gives
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(a)

(b)

Figure 3-1 The setup of the rMet model recapitulates the metastatic migration
from a mammary environment, located in the top transwell, to a secondary
site, the bone, located at the bottom (a). Cells are seeded in the top transwell
[(b) left], and after 7-14 days of culture in the model, give rise to three distinct
populations of cells [(b) right].
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rise to three distinct populations: 1) the cells on the top, remaining within the transwell,
which form tumor-like clusters, 2) the cells that have migrated through Matrigel to the
transwell membrane, but have remained attached, deemed the ‘invasive’ layer, and 3)
the cells that have migrated and colonized the rBM. After approximately 5 days of
culturing cells in the rMet model, interesting morphologies were observed in a population
of cells that migrate to the rBM. These cells resemble neurons in that they have
multiple, axon-like extensions and do not closely resemble mesenchymal or epithelial
morphology that is characteristic of cancer cells (Figure 3-2). This observation has led
to the current hypothesis that neuronal growth factors could play an important role in
breast cancer metastasis.
It is known that neurotrophins are important factors in neuronal growth and
development, but it could be possible that they could exert their effects to non-neuronal
cell types as well. It has been difficult to determine all of the pathways that are involved
with neurotrophin signaling because the pathway activation depends on the
neurotrophin, receptor, and subsequent receptor dimerization. It is known that when
NGF binds to TrkA and it homodimerizes that the MAPK pathway is activated45. This
leads to cell proliferation. The signaling pathways involved with the other two
neurotrophins, BDNF and NT4/5 and their receptors are less obvious and could lead to a
variety of activated pathways. Thus, it is necessary to determine if the treatment with
these neurotrophins can also lead to activation of a proliferative pathway.
Cancer is characterized by a variety of characteristics, but particularly by
the unchecked growth and proliferation of cancer cells. This proliferative quality of
cancer is a good potential target for treatment. Current efforts to treat this have limited
success, particularly in metastasis, which has led to new avenues of research to try and
overcome this. In order to discover possible therapeutic targets, however, more must be
understood about the signaling pathways that are involved. Due to an observation of
phenotypic plasticity in metastatic cancer cells that results in cells that resemble
neurons, a new path of research has led us to investigate whether neuronal growth
factors such as neurotrophins could be involved in the proliferation of metastatic breast
cancer cells. In order to determine this interaction it is important to first determine if the
neurotrophin receptors, p75NTR, TrkA, and TrkB are expressed in an aggressive
metastatic cancer line, such as MCF10CA1a, using both 2-D and 3-D cell culture. After
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Figure 3-2 A population of cells that colonize the rBM fraction have a neuronallike morphology. The cells display multiple axon-like extensions, black arrowhead
(a), and axon-like extensions that are uncharacteristically long for cancer cells,
white arrowhead (b).
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the confirmation of neurotrophin receptor expression, the proliferative effects of
neurotrophins can be tested.
3.2 Neurotrophin Receptor Identification
3.2.1 2-D Cell Culture
The first step to determine neurotrophin signaling in breast cancer metastasis, is
to determine whether the neurotrophin receptors are expression by the metastatic breast
cancer cells. The cell line of interest is MCF10CA1a, which is a malignant breast
epithelial cell line, and was chosen because of its aggressive growth and migratory
capabilites in the rMet model. Figure 3-3 shows the expression of the three selected
neurotrophin receptors, NGFR(p75NTR), TrkA, and TrkB, in MCF10CA1a cells in 2-D
culture. All three receptors are expressed in MCF10CA1a cells in 2-D. NGFR and TrkB
have a heterogeneous expression in the cell line, while TrkA expression seems quite
consistent with all cells (Figure 3-3). In addition, the expression of NGFR and TrkA is
localized to the plasma membranes of cells, while the experession of TrkB is seems
more cytoplasmic.
3.2.2 3-D Cell Culture
It is important to also determine the expression of the neurotrophin receptors in
3-D culture. Due to the fact that 2-D and 3-D cell culture are quite different, there is a
possibility that the expression of the receptors is also different. In order to accomplish
this, the rMet model was used to set-up the tissue microenvironment in 3-D. Because
the rMet model gives rise to three distinct populations of cells, it is important to establish
receptor expression in all three layers: the primary tumor fraction, invasive fraction, and
rBM colonizing fraction. After 14 days culture in the model, each population was
recovered from the ECM and stained for the three neurotrophin receptors. Figure 3-4
shows the expression of the receptors at the different levels. At the top of the rMet,
there is a small population of cells that are positive for NGFR, TrkA, and TrkB (Figure 34(a)). The cells express the receptors in a very heterogeneous manner and the
expression is greatest in cells that are located in clusters. Progression down to the
invasive (Figure3-4(b)) and rBM (Figure 3-4(c)) layers show higher number of cells
positive for each the receptor, though the heterogeneity of receptor expression is
retained in all fractions within the rMet. This shows that in a more physiologically
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Figure 3-3 Immunofluorescence of neurotrophin receptor expression in 2-D in
MCF10CA1a cells. Cells were cultured in a chamber slide for 24 hours and then
stained for the receptors. Scale bar 50 µM.
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Figure 3-4 Immunofluorescence of neuotrophin receptor expression in the
rMet model in MCF10CA1a cells. Cells were cultured in the model for 14 days
and then isolated from each fraction to be stained for the receptors.
Immunofluorescence of nuerotrophin receptor expression in the primary tumor
fraction (a) is low and distinct to clusters of cells. The expression in the
invasive layer (b) and rBM fraction (c) are expressed over a wider variety of
cells, though still heterogeneous. Scale bar, 50 µm.
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relevant setting, MCF10CA1a cells do express the three neurotrophin receptors with
higher proportion expressed by the cells with migratory capacity.
3.2.3 rt-qPCR Confirmation of Neurotrophin Receptor Expression
To confirm that the cells do in fact express the three neurotrophin receptors, RTPCR was perform to quantify the mRNA expression levels of each receptor. Primers
were designed to the extracellular domains of each three receptor64. RNA was extracted
from MCF10CA1a cells from the flask (2-D), and from the top and rBM fractions of the
rMet model (3-D). The results show that there is first is a low expression of all three
receptors in 2-D culture. For all three receptors, there is an increase in the expression
when the cells are cultured in the rMet model. Further, cells that are capable of
migrating and surviving in the rBM fraction show a very large upregulation of all three
neurotrophin receptors. TrkA (Figure 3-5b) has the highest fold change in the rBM,
where the expression is upregulated approximately 240-fold as compared to the cells in
the top. This similar pattern, is seen in both NGFR (Figure 3-5a) and TrkB (Figure3-5c)
as well.
3.3 Neurotrophins and their effects on Breast Cancer Cell Proliferation
3.3.1 2-D Cell Culture
MCF10CA1a cells were treated with varying concentrations of neurotrophins:
NGF, BDNF, and NT4/5 in 2-D cell culture to determine the proliferative effects that they
have on the cells, and to determine the most effective concentration of each particular
neurotrophin. Data was collected at 24- and 48-hours post neuorotrophin treatment for
each concentration. For NGF (Figure 3-6a) and NT 4/5 (Figure 3-6c) the most effective
concentration between 24 and 72 hours was 5 ng/ml. This is the concentration in which
the proliferation of cells was significantly larger at 72 hours than it was at 24. For BDNF
(Fig 3-6b) the most effective concentration was 50 ng/ml. It is important to choose the
particular concentration that has a pro-proliferative effect on the cells because it has
been shown that there are both pro- and anti-proliferative effects of neurotrophins
depending on their concentration. These results show that there is a concentration
dependent effect of neurotrophins on the proliferation of MCF10CA1a cells.
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(a)

(b)

(c)

Figure 3-5 Fold change in each of the receptors for MCF10CA1a cells in 2D
and from two fractions of the rMet model. RT-qPCR was completed using
mRNA from cells cultured in 2D, and cells isolated from the primary tumor site
and the rBM fraction of the rMet model. The neurotrophin receptor genes are
expressed in 2-D and are upregulated in the primary tumor fraction and further
upregulated in the rBM colonizing fraction. The greatest upregulation is TrkA
(b) in the rBM, followed by TrkB (c) in the rBM.
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(a)

(b)

(c)

Figure 3-6 Effects of neurotrophins on proliferation of MCF10CA1a cells in 2D
culture. Viable cells were counted using Trypan-blue and a hemacytometer.
Graphs show the most effective concentrations for each neurotrophin. The
most effective concentrations for NGF (a) and NT 4/5 (c) are 5 ng/ml, p<0.05.
The most effective concentration for BDNF is 50 ng/ml, p<0.01.
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3.3.2 rMet Model
Based on 2-D proliferation experiments, the most effective concentrations for
each neurotrophin were used in a proliferation experiments in the rMet model. The
concentrations chosen were 50 ng/ml for BDNF, and 5 ng/ml for both NT4/5 and NGF.
MCF10CA1a cells were cultured in the rMet model for 14 days. At that point, the
transwell was removed from the rBM fraction and a treatment of neurotrophin in reduced
serum media was added. This was done to specifically treat the population of migratory
cells that are able to migrate and survive in the rBm fraction. In order to determine
proliferation, cells were stained with Ki67, a marker for proliferation, at 24- and 72-hours
post neurotrophin treatment. The longer time point in this experiment was chosen
because original optimization of the experiment revealed little to no difference in the
results between 24 and 48 hours. The results at 24 hours (Figure 3-7a) show that NGF
stimulates the highest level of proliferation among all of the neurotrophins. This is
consistent with other publications that have cited NGF as a mitogenic factor for MCF7
cells, but not for noncancerous cells68. Seventy-two hours post neurotrophin treatment
(Figure 3-7b) shows a slight increase in proliferation of cells treated with NGF, but more
significantly, there is a large reduction in the proliferation of cells treated with BDNF. At
24 hours, BDNF does not show a significant increase in proliferation, suggesting that
adding additional BDNF to cells in the rBM fraction could be detrimental to their
proliferative capabilities.
In order to determine the potential effects that neurotrophins can have on
metastatic cancer cells, a series of experiments determining the role of neurotrophins
and their effects on cancer cell proliferation were completed. There is some evidence
that certain neurotrophins can induce proliferation of breast cancer cells, but do not have
an effect on non-cancerous cells. Particularly, there is evidence that NGF has a
mitogenic effect on MCF7 and MDA-MB-231 cells68. The work completed on metastatic
breast cancer lines, however, is lacking and needs further elucidation. Further, most
research with neurotrophins and breast cancer cell lines has been completed in 2-D cell
culture, where cells are grown on the surface of the tissue culture plastic. 2-D cell
culture work is a good foundation on which to begin, but lacks physiological relevance
due to a number of shortfalls, including lack of ECM components. It is important that in
vitro cancer research mimics physiologically relevant conditions, which makes 3-D cell
culture a vital avenue to take.
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(a)

(b)

Figure 3-7 Effects of neurotrophins on proliferation of MCF10CA1a cells in the
rMet model. In order to determine proliferation, cells were stained with Ki67, a
marker of proliferation, and the total percentage of cells positive were
determined. At 24 hours post-neurotrophin treatment, NGF causes the
greatest increase in proliferation (p-value=0.3677) (a). At 72 hours posttreatment, BDNF decreases the proliferation of the cells (p-value=0.179), with
a small increase in NGF (b).
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3.4 Neurotrophins and Cancer Cell Migration
Neurotrophins are vital players in the migration of neuronal cells during
development. With evidence that neurotrophins can exert their effects on non-neuronal
cells, and with the confirmation that MCF10CA1a cells express the three neurotrophin
receptors, we wanted to determine whether the neurotrophins exert an effect on the
migration and dissemination of breast cancer cells during metastasis. There have been
a handful of studies that have studied the effects of neurotrophins and the effects that
they have on the migration and invasiveness of cancer cells. Despite this, however, still
little is known about the receptors involved and which particular signaling pathways are
involved in this. For example, Lagadec et al. discovered an increase in TrkA expression
in breast cancer tumors and discovered that the overexpression of TrkA in MDA-MB-231
cells increased their invasiveness69. Further, it has been shown that neurotrophins NGF
and NT 4/5 increase the migration and invasive properties of prostate cancer cell lines in
a dose-dependent manner70. This is consistent with other studies showing that addition
of neurotrophins NGF and NT4/5 increase the invasiveness of pancreatic and ovarian
cancer cells71,72. Despite these studies, there is still gaping knowledge on how the
increased invasiveness can aid in the treatment of metastasis. This leads to the current
vein of research, to determine if similar migratory effects can be seen in aggressive
breast cancer cell lines. The activation of signaling pathways leading to migration and
invasion are not very clear in cancer cells, but further work should be able to elucidate
the relationship between neurotrophins, the NTRs and their signaling pathways. It has
been suggested that TrkA has the biggest influence on invasion of cancer cells, but this
data needs more confirmation. Metastasis is a complex process that is extremely hard
to target with current treatments. Current treatments and morbidity of breast cancer due
to metastasis can be greatly improved if a signaling pathway and model of activation can
be determined.
3.5 Neurotrophins and MCF10CA1a Cell Migration: Dome Assay
In order to determine the role that neurotrophins play in the migration of breast cancer
cell lines, a dome assay was created to determine the chemotactic potential of the
neurotrophins on MCF10CA1a cells. In this assay, cells are mixed with Matrigel and are
seeded in a dome in the center of a well in a tissue culture plate. In the surrounding
area of the well, the treatment ring, Matrigel is added with the concentrations of
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neurotrophins that were deemed most effective in the 2-D proliferation study (Figure 38). These concentrations are also fairly consistent with the concentrations used in other
migration studies. After 24 hours, cells were imaged and counted based on their
migration out of the dome and into the cell-free ring of Matrigel. The neurotrophin with
the greatest stimulation of migration was NGF, with over 10% of cells migrating to the
treatment ring (Figure 3-9). NT 4/5 had over a 3% increase in cell migration, which is a
significant portion of cells compared to the vehicle control. BDNF had no significant
effect on the migration of cells in the dome assay.
3.6 Neurotrophins and their receptors as potential treatment targets in breast cancer
In this study, we can see that neurotrophins can play a role in the proliferation of
breast cancer cells. In both 2-D and 3-D cell culture, MCF10CA1a cells express three
neurotrophin receptors. Further, in 3-D, the migratory cells that colonize and proliferate
in the rBM upregulate the receptors, which is evidence that highly migratory cells might
be more receptive to neurotrophic effects. This is extremely useful and also congruent
with the results that have shown that breast cancer tumors overexpress TrkA. If cells
that have shown that they are capable of migrating and surviving in a secondary
location, upregulate the neurotrophin receptors, they may be more receptive to
neurotrophins than normal cells, which could greatly improve treatment options for
breast cancer. Further, with the increase of the expression of the neurotrophin
receptors, it could be expected that neurotrophins could possibly have increased effects
in breast cancer cells. In 2-D cell culture we see an increase in cell proliferation at
particular concentrations of neurotrophins. We also see that cells in the rBM have a
slight increase in proliferation in the presence of NGF, which is consistent with the
upregulation of TrkA in these cells because TrkA is the high-affinity receptor for NGF.
Metastatic cells that are able to colonize at distant sites and form micrometastases must
have increased proliferative properties in order to survive for an extended period of time
at a distant site. It is possible that these cells are exploiting certain receptors and
signaling pathways to increase their survival. If an effective inhibitor of TrkA could be
developed, this could possibly have an effect on the unchecked proliferation that is
characteristic of breast cancer cells.
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Figure 3-8 Setup of the Dome Assay

Figure 3-9 Dome Assay for Migration NT 4/5 and NGF induce a
significant increase in cell migration towards the neurotrophin stimulus
(**p-value <0.01; ***p-value<0.0001).
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We have also looked at the increase in migratory capabilities of MCF10CA1a cells in 3-D
cell culture when exposed to neurotrophins. In 3-D there is a significant increase in
expression of TrkA and TrkB. These two receptors bind both NT 4/5 and NGF, which is
consistent with the increased invasiveness that is seen in the dome assay when these
two neurotrophins added. NT 4/5 and NGF both act as a chemoattractant in the assay,
showing that these cells are attracted to, and benefit from being in the presence of these
neurotrophins. Because metastasis is so difficult to treat and current treatments are
extremely limited, these results show a vital avenue that must be explored in the
treatment of metastasis. Cells that are able to migrate to distant sites in the body are
exploiting pathways that increase their migration and invasion capabilities.
Neurotrophins and their pathways help with neuronal migration and have been shown
now to have an effect on the migration of breast cancer cells. It is now important to
determine ways in which to block these receptors or the signaling pathways that are
downstream of them in order to decrease migration and possibly find a way to decrease
metastatic potential of breast cancer cells.
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CHAPTER 4. NEUROTROPHINS AND THEIR POTENTIAL FOR THE TREATMENT
OF BREAST CANCER AND ITS METASTASIS

Breast cancer is a devastating disease that is the most common cancer in
women, with the exception of skin cancer1. It accounts for nearly 14 percent of all
reported cancer1. The largest obstacle to overcome in terms of breast cancer, is
metastasis, which accounts for approximately 90 percent of breast cancer morbidity2.
Metastasis is a complex process whereby cells from a primary tumor site in the
mammary gland are able to migrate and seed in a secondary location in the body. This
process involves many steps, is extremely difficult to pinpoint and treat, and accounts for
the greatest morbidity and mortality in breast cancer. The expected rate of metastasisrelated breast cancer deaths in 2014 is over 209,000. As the rate of breast cancer
metastasis increases approximately 2 percent every year3, it becomes more important
for the scientific community to determine signaling pathways that are involved in the
proliferation and migration of breast cancer cells, in order to develop treatments against
them.
Here I present an interesting avenue of research where we combine our
knowledge of neuronal growth factors and their receptors and their possible role in
cancer metastasis. An observation of multiple metastatic cancer lines in the rMet model
have revealed a type of phenotypic plasticity where a population of have similar
morphology to that of neuronal cells. The rMet model is a method in which to
recapitulate the complexities of the metastatic spread. In the model, cells are seeded in
‘primary tumor site’ with ECM components of the mammary gland in a transwell. This
transwell is inserted into a well with media and ECM components characteristic of a
‘distant metastatic site’ in our case the bone. In the setup of the rMet model, we noticed
that a population of the cells that are able to transverse the top well and membrane,
survive in a nonadherent state in the media and successfully survive in the bottom, or
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rBM portion of the model have neuronal morphology. This phenomenon consistently
occurs across many cancer cell lines tested, which has led to the current vein of
research combining what we know of neuronal growth factors and coupling them to the
migratory and proliferative qualities of metastatic breast cancer cells. Neurotrophins are
important growth factors for the migration and proliferation of neurons32. With evidence
that they have effects on cancerous cells70-72, there is an opportunity to discover which
pathways they could possibly activate and if there is an option to use these pathways as
a treatment for either or both the proliferation of breast cancer cells, and their invasive
and migratory capabilities.
We have shown here, that the aggressive metastatic breast cancer cell line,
MCF10CA1a, not only expresses all three neurotrophin receptors of interest, but also
that in the rMet model, the cells that migrate and colonize the reconstructed bone
marrow matrix significantly upregulate their expression of TrkA, TrkB, and NGFR. The
binding of NGF to TrkA and p75NTR has been shown to activate the MAPK pathway,
which would account for the proliferative effects seen when NGF is added to the cultures
of MCF10CA1a cells. This upregulation of TrkA and NGFR could also account for the
increased migratory capabilities that were observed when NGF and NT4/5 were added
to the cultures of breast cancer cells. An important avenue that would need to be
explored here is to quantify the phosphorylation of Src family kinases activated upon
neurotrophin binding to TrkA to pinpoint the exact pathways that are being utilized for
cancer cell proliferation and migration. Furthermore, TrkB is also upregulated in rBM
colonizing breast cancer cells, but less is known about the subsequent pathways that
are activated when either BDNF or NT4/5 bind to it. These pathways could possibly lead
to resistance to apoptosis, invasion, or even proliferation of cancer cells.
Here we show that addition of NT4/5 leads to increased migration of breast cancer cells,
which would require the further investigation of the pathways activated downstream of
neurotrophin. If the activation of these pathways can be determined, this would be a
useful treatment option for both the proliferation and invasive qualities of metastatic
breast cancer cells. Blocking TrkA and NGFR could lead to decreased proliferation of
breast cancer cells and decreased migratory capabilities. This coupled with the
knowledge that neurotrophins do not have the same effects on noncancerous cells68,
could be used to treat this devastating disease. Current treatments such as tamoxifen
citrate, anastrozole and other chemotherapeutic treatments lead to terrible side effects,
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such as nausea, hair loss, and anemia for patients because these medications are often
not able discern between cancerous and noncancerous cells. If neurotrophins do indeed
affect cancer cells, but not normal cells, this could increase the efficacy of cancer
treatment. Further, this research leads us to a treatment that may in fact be able to treat
the most difficult aspect of breast cancer, metastasis. Continued research is needed to
complete this model, but here we propose that neurotrophins can have an effect on the
proliferation and migratory capabilities of breast cancer cells. From here, there is a
possibility that blocking their receptors, TrkA, TrkB, or p75NTR, which are over expressed
in metastatic cancer cell populations, could lead to decreased activity of proliferation and
migration signaling pathways.
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